Related Articles
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS
PI3K inhibition sensitizes EGFR wild‑type NSCLC cell lines to erlotinib chemotherapy